361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797630588121776128 |
|---|---|
| author | John WM Martens Reno Debets Justine Michaux Michal Bassani-Sternberg Dian Kortleve Sonja Buschow Monique de Beijer Dora Hammerl Mandy Van Brakel Rebecca Wijers Daphne Roelofs Madelon Badoux Mieke A Timmermans Anita C Liao Erik Danen Rachel JM Abbott |
| author_facet | John WM Martens Reno Debets Justine Michaux Michal Bassani-Sternberg Dian Kortleve Sonja Buschow Monique de Beijer Dora Hammerl Mandy Van Brakel Rebecca Wijers Daphne Roelofs Madelon Badoux Mieke A Timmermans Anita C Liao Erik Danen Rachel JM Abbott |
| author_sort | John WM Martens |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:09:15Z |
| format | Article |
| id | doaj.art-33e6a6cb5cf54edbbedf27bd1eb6a7b0 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:09:15Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-33e6a6cb5cf54edbbedf27bd1eb6a7b02023-11-12T05:05:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0361361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancerJohn WM Martens0Reno Debets1Justine Michaux2Michal Bassani-Sternberg3Dian Kortleve4Sonja Buschow5Monique de Beijer6Dora Hammerl7Mandy Van Brakel8Rebecca Wijers9Daphne Roelofs10Madelon Badoux11Mieke A Timmermans12Anita C Liao13Erik Danen14Rachel JM Abbott155 Department of Medical Oncology and Cancer Genomics Netherlands, Erasmus MC Cancer Institute/Erasmus University Medical Center, Rotterdam, The NetherlandsLaboratory of Tumor Immunology, Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The NetherlandsDepartment of Oncology, University Hospital of Lausanne, Lausanne, SwitzerlandLudwig Institute for Cancer Research, University of Lausanne, Lausanne, Switzerland2Erasmus MC Cancer Institute, Rotterdam, NetherlandsGastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, The Netherlands1Erasmus MC University Medical Center, Rotterdam, Netherlands1Pan Cancer T, Rotterdam, Netherlands2Erasmus MC Cancer Institute, Rotterdam, Netherlands2Erasmus MC Cancer Institute, Rotterdam, Netherlands1Pan Cancer T, Rotterdam, Netherlands1Pan Cancer T, Rotterdam, Netherlands2Erasmus MC Cancer Institute, Rotterdam, Netherlands3Leiden Academic Centre for Drug Research, Leiden, Netherlands3Leiden Academic Centre for Drug Research, Leiden, Netherlands1Pan Cancer T, Rotterdam, Netherlands |
| spellingShingle | John WM Martens Reno Debets Justine Michaux Michal Bassani-Sternberg Dian Kortleve Sonja Buschow Monique de Beijer Dora Hammerl Mandy Van Brakel Rebecca Wijers Daphne Roelofs Madelon Badoux Mieke A Timmermans Anita C Liao Erik Danen Rachel JM Abbott 361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer Journal for ImmunoTherapy of Cancer |
| title | 361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer |
| title_full | 361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer |
| title_fullStr | 361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer |
| title_full_unstemmed | 361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer |
| title_short | 361 T cell receptor specific for tumor-restricted Ropporin-1 to treat triple negative breast cancer |
| title_sort | 361 t cell receptor specific for tumor restricted ropporin 1 to treat triple negative breast cancer |
| work_keys_str_mv | AT johnwmmartens 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT renodebets 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT justinemichaux 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT michalbassanisternberg 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT diankortleve 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT sonjabuschow 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT moniquedebeijer 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT dorahammerl 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT mandyvanbrakel 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT rebeccawijers 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT daphneroelofs 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT madelonbadoux 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT miekeatimmermans 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT anitacliao 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT erikdanen 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer AT racheljmabbott 361tcellreceptorspecificfortumorrestrictedropporin1totreattriplenegativebreastcancer |